StockData
Regentis Biomaterials Ltd. logo

Regentis Biomaterials Ltd. (RGNT) stock

RGNTNYSEOrthopedic, Prosthetic & Surgical Appliances & SuppliesFiscal year ends December 31
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Feb 24, 2026Score 1/30
$1.14−0.08 (-6.56%)

Close on Nov 18, 2026Market cap $5.90MP/E –Yield –

Regentis Biomaterials operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

For fiscal 2025 it was -$6.97M, down 847.6% from the year before.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$6.97M-847.6%
FY2024Dec 31, 2024$932.00K–
FY2023Dec 31, 2023-$1.93M–

More Regentis Biomaterials figures

See a number that looks wrong?